ReviewBioactive materials2023
Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy.
Review in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Graphene Quantum Dots for Glioblastoma Treatment and Detection-Systematic Review.Molecules (Basel, Switzerland) · 2025Pooled it
- Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.Materials today. Bio · 2026Article
- Revolutionizing Breast Cancer Treatment: Harnessing Ehrlich Ascites Carcinoma Model, Cancer Metabolism, and Nanotechnology-Enhanced Chemotherapy for Improved Patient Outcomes.Cell biochemistry and biophysics · 2026Review
- Glutathione-Responsive Supramolecular Micelles Based on β-Cyclodextrin Construction: Combining Photodynamic Therapy and Chemotherapy for Cancer Treatment.Pharmaceutical research · 2025Article
- All-in-one peptide with sequential pH gradient sensing capabilities for the targeted delivery and deep penetration of nanomicelles against breast cancer.Asian journal of pharmaceutical sciences · 2025Article
- Bufotalin loaded biomimetic nanodrug for combined chemo/photodynamic therapy of cancer.Materials today. Bio · 2025Article
- Mechanotransduction for therapeutic approaches: Cellular aging and rejuvenation.APL bioengineering · 2025Review
- Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer.Materials today. Bio · 2025Article
- Multi-Response Au-Nanohybrid Composite Triggered NIR-Light for Effective Anti-Tumor Therapy in Animal Model.International journal of nanomedicine · 2025Article
- Facile Synthesis of Designer Shape-Defined Mesoporous Metal Nanoenzymes as Therapeutics for Diseases Involving Excessive Oxidative Stress.Biomaterials research · 2025Article
- Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer.Current pharmaceutical biotechnology · 2025Review
- Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms.Journal of nanobiotechnology · 2024Article
- Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer.Acta pharmaceutica Sinica. B · 2024Review
- Biomineralized apoferritin nanoparticles delivering dihydroartemisinin and calcium for synergistic breast cancer therapy.Scientific reports · 2024Article
- pH-responsive magnetic CuFeScientific reports · 2024Article
- Neurosurgical management of primary and secondary brain tumors: new horizons and emerging strategies.Neurosurgical review · 2024Article
- Cancer immunotherapy and its facilitation by nanomedicine.Biomarker research · 2024Review
- Polymersomes as Innovative, Stimuli-Responsive Platforms for Cancer Therapy.Pharmaceutics · 2024Review
- Targeting triple negative breast cancer stem cells using nanocarriers.Discover nano · 2024Review
- NK cell-based tumor immunotherapy.Bioactive materials · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical resection remains a mainstay in the treatment of malignant solid tumors. However, the use of neoadjuvant treatments, including chemotherapy, radiotherapy, phototherapy, and immunotherapy, either alone or in combination, as a preoperative intervention regimen, have attracted increasing attention in the last decade. Early randomized, controlled trials in some tumor settings have not shown a significant difference between the survival rates in long-term neoadjuvant therapy and adjuvant therapy. However, this has not hampered the increasing use of neoadjuvant treatments in clinical practice, due to its evident downstaging of primary tumors to delineate the surgical margin, tailoring systemic therapy response as a clinical tool to optimize subsequent therapeutic regimens, and decreasing the need for surgery, with its potential for increased morbidity. The recent expansion of nanotechnology-based nanomedicine and related medical technologies provides a new approach to address the current challenges of neoadjuvant therapy for preoperative therapeutics. This review not only summarizes how nanomedicine plays an important role in a range of neoadjuvant therapeutic modalities, but also highlights the potential use of nanomedicine as neoadjuvant therapy in preclinical and clinic settings for tumor management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.